[{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merrimack Pharmaceuticals \/ Merrimack Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Merrimack Pharmaceuticals \/ Merrimack Pharmaceuticals"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merrimack Pharmaceuticals","amount2":1.03,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Infusion","sponsorNew":"Merrimack Pharmaceuticals \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Merrimack Pharmaceuticals \/ Ipsen"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Merrimack Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"MM-398","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Merrimack Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Merrimack Pharmaceuticals \/ Merrimack Pharmaceuticals"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"MM-398","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"MM-151","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"MM-151","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"MM-151","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"MM-111","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"MM-111","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase I","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"MM-310","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"MM-141","moa":"Insulin-like growth factor I receptor | Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase II","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"MM-141","moa":"Insulin-like growth factor I receptor | Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase I","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"MM-302","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"MM-302","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"MM-121","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase II","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"MM-121","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase II","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merrimack Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Merrimack Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"MM-121","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase II","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Merrimack Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Elevation Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"MM-121","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase II","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Merrimack Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Merrimack Pharmaceuticals \/ Merrimack Pharmaceuticals"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"MM-121","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase I","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Merrimack Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"MM-121","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase I","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Merrimack Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"MM-121","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase I","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Merrimack Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Seribantumab","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase I","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Merrimack Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Merrimack Pharmaceuticals \/ Merrimack Pharmaceuticals"}]
Find Clinical Drug Pipeline Developments & Deals by Merrimack Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
